Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2003
04/10/2003WO2003028739A2 Composition for preventing or treating hyperlipidemia or hyperglycemia comprising a polymer or its salt
04/10/2003WO2003028738A2 Anti-infectious carbohydrates
04/10/2003WO2003028737A1 Anti-viral agents and in-vitro method for the identification of candidates able to inhibit binding of polymerase to epsilon
04/10/2003WO2003028736A2 Pharmaceutical preparations comprising alkyl phosphocholine compounds in liposomes which may be sterile-filtered or heat-sterilised
04/10/2003WO2003028735A1 Estrogen/gestagen combination preparation and application thereof
04/10/2003WO2003028734A1 Triazepine derivatives as neurotrophic agents
04/10/2003WO2003028733A1 Tetracyclic indole derivatives as 5-ht receptor ligands
04/10/2003WO2003028732A1 Receptor antagonist
04/10/2003WO2003028731A1 Chk1 kinase inhibitors
04/10/2003WO2003028730A2 Pharmaceutical combinations of pde-v inhibitors and other agents
04/10/2003WO2003028729A2 Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
04/10/2003WO2003028728A1 4-(4-substituted piperazinyl-1yl)-butylcarboxamides as d3 dopamine subtype selective ligands
04/10/2003WO2003028727A1 3-`hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7,8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors
04/10/2003WO2003028726A1 Quinoline derivatives as neuropeptide y antagonists
04/10/2003WO2003028725A1 4-(1-piperidiny)-butylcarboxamide as d3 dopamine receptor subtype selective ligands
04/10/2003WO2003028724A1 Chk1 kinase inhibitors
04/10/2003WO2003028723A1 Pharmaceutical compositions for percutaneous absorption containing fused imidazopyridine derivatives
04/10/2003WO2003028722A1 Treatment of hepatitis b virus infection with human monoclonal antibodies
04/10/2003WO2003028721A2 Substituted benzimidazole compounds and their use for the treatment of cancer
04/10/2003WO2003028720A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
04/10/2003WO2003028719A1 Substituted 2,5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases
04/10/2003WO2003028718A1 Novel formulations of carvedilol
04/10/2003WO2003028717A1 A drugs association against influenza virus
04/10/2003WO2003028716A1 Aqueous ecabet sodium solution preparation
04/10/2003WO2003028715A2 Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis
04/10/2003WO2003028714A2 Antioxidant combination composition and use thereof
04/10/2003WO2003028713A2 3,4-methylenedioxy-substituted chalcones as therapeutic agents
04/10/2003WO2003028712A2 Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
04/10/2003WO2003028711A2 Use of c-kit inhibitors for the treatment of myeloma
04/10/2003WO2003028710A2 Compounds for reducing excessive intake of food
04/10/2003WO2003028709A2 Use of mannosamine derivatives for the stimulation of neurite growth
04/10/2003WO2003028708A1 Timed, sustained release multi-particulate dosage forms of propranolol
04/10/2003WO2003028707A1 Solid compositions comprising ramipril
04/10/2003WO2003028705A1 Pharmaceutical compositions comprising colloidal silicon dioxide
04/10/2003WO2003028704A1 Extended release pharmaceutical composition containing metformin
04/10/2003WO2003028702A1 Ibuprofen salt emulsifiers and cream formulations containing same
04/10/2003WO2003028701A2 Liposomes containing (ether)lysolecithins
04/10/2003WO2003028700A2 Water soluble nanoparticles of hydrophilic and hydrophobic active materials
04/10/2003WO2003028699A1 Compositions used to alleviate xerostomia and to treat disorders associated with same
04/10/2003WO2003028697A2 Liposome loading with metal ions
04/10/2003WO2003028696A2 Compositions for delivery of drug combinations
04/10/2003WO2003028692A2 Acne treatment using oleanolic acid
04/10/2003WO2003028690A1 Cosmetic and dermatological stick
04/10/2003WO2003028674A2 Method for stimulating hair growth by administering vitamin d analogs
04/10/2003WO2003028667A2 Semisolid topical hormonal compositions and methods for treatment
04/10/2003WO2003028665A2 Methods for the purification of levofloxacin
04/10/2003WO2003028664A2 Preparation of levofloxacin and forms thereof
04/10/2003WO2003028659A2 Methods and compositions for modulating apoptosis
04/10/2003WO2003028656A2 Adjuvant compositions
04/10/2003WO2003028653A2 Sustained release pharmaceutical compositions
04/10/2003WO2003028652A2 Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis
04/10/2003WO2003028651A2 Antipsychotic agents stimulate neurogenesis in brain
04/10/2003WO2003028650A2 Benzimidazolidinone derivatives as muscarinic agents
04/10/2003WO2003028649A2 Novel composition of carvedilol
04/10/2003WO2003028648A2 Veterinaire florfenicol formulation that is syringeable under cold weather conditions
04/10/2003WO2003028646A2 Methods of treating drug-resistant bacterial infections
04/10/2003WO2003028642A2 Methods of inhibiting metastases
04/10/2003WO2003028641A2 Mch receptor antagonists
04/10/2003WO2003028634A2 Method of treatment using ligand-immunogen conjugates
04/10/2003WO2003028633A2 Parenteral delivery systems
04/10/2003WO2003028630A2 Methods and compositions for modulating interleukin-21 receptor activity
04/10/2003WO2003028624A2 Levothyroxine compositions and methods
04/10/2003WO2003028623A2 Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucuous membranes
04/10/2003WO2003028622A2 Method of delivering drugs to a tissue using drug-coated medical devices
04/10/2003WO2003028600A1 Wipe formulation
04/10/2003WO2003028537A2 Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer
04/10/2003WO2003028527A2 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
04/10/2003WO2003028459A1 Nicotinic acid-heterocyclyl-amides and analogous pyrimidine derivatives serving as pesticides
04/10/2003WO2003028458A1 N-thio-nicotinamide derivatives and related compounds for use as pesticides
04/10/2003WO2003028457A1 Method of restoring ciliated cell motility
04/10/2003WO2003015711A9 Combination motif immune stimulatory oligonucleotides with improved activity
04/10/2003WO2003013563A3 Mineral-protein preparations (mpp) and neuropathies in diabetes
04/10/2003WO2003011300B1 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
04/10/2003WO2003004734A9 Method for the production of low defect density silicon
04/10/2003WO2003004493A8 Novel compounds, their preparation and use
04/10/2003WO2003002115A3 Substituted benzimidazoles for controlling endoparasites
04/10/2003WO2003002103A3 Hydrophobic dopamine agonists administered to the dermis
04/10/2003WO2003000861A9 Eukaryotic genes involved in adult lifespan regulation
04/10/2003WO2003000709A9 Sialic acid derivatives for use as siglec inhibitors
04/10/2003WO2003000178A3 Black soybean polysaccharides
04/10/2003WO2003000175A3 Pediatric formulation of gatifloxacin
04/10/2003WO2003000118A3 Method for enhancing the effectiveness of cancer therapies
04/10/2003WO2002103971A3 Multicarrier receiver
04/10/2003WO2002102978A3 Human growth hormone antagonists
04/10/2003WO2002102793A3 Quinazolinediones as antibacterial agents
04/10/2003WO2002102394A3 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
04/10/2003WO2002100417A3 Use of glycosaminoglycans for the treatment of hiv-associated nephropathy
04/10/2003WO2002100348A8 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
04/10/2003WO2002096467A3 Pharmaceutical use for secreted bacterial effector proteins
04/10/2003WO2002094830A8 Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists
04/10/2003WO2002094203A3 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
04/10/2003WO2002094189A3 Compositions and methods for treating or preventing convulsions or seizures
04/10/2003WO2002092064A3 Therapeutic method for inducing tolerance
04/10/2003WO2002083108A3 Compositions containing cgmp pde inhibitors and local anaesthetic agents for nasal application
04/10/2003WO2002083105A3 Composition for enhanced absorption of nsaids
04/10/2003WO2002083103A3 Pharmaceutical product with reticulated crystalline microstructure
04/10/2003WO2002083079A9 Aerosol compositions containing formoterol for delivery to the lungs via nebulization
04/10/2003WO2002081668A8 Desaturase genes and uses thereof
04/10/2003WO2002078639A3 A method of treating proliferative diseases using eg5 inhibitors
04/10/2003WO2002076472A3 Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
1 ... 5504 5505 5506 5507 5508 5509 5510 5511 5512 5513 5514 5515 5516 5517 5518 5519 5520 5521 5522 5523 5524 ... 7860